Literature DB >> 12881333

Comparison of iridial pigmentation between latanoprost and isopropyl unoprostone: a long term prospective comparative study.

T Chiba1, K Kashiwagi, N Chiba, K Ishijima, M Furuichi, S Kogure, K Abe, S Tsukahara.   

Abstract

AIM: To compare incidence of iridial pigmentation prospectively induced by long term treatment with latanoprost and isopropyl unoprostone (hereafter, unoprostone) in Japanese patients with glaucoma.
METHODS: Patients with glaucoma treated with prostaglandin (PG) related ophthalmic solutions were sequentially enrolled. Patients treated for more than 30 months with PG related ophthalmic solutions were subjected to analysis. The entry criteria were no history of intraocular surgery, laser iridotomy, and/or laser trabeculoplasty within 12 months before and after the enrolment; and no history of uveitis; no changes in antiglaucoma drugs within 6 months before and after the enrolment. Photographs of the irides were taken under the same conditions and three glaucoma specialists evaluated the iridial pigmentation with masking of patient information. The correlation of iridial pigmentation with the background factors and the reduction of intraocular pressure (IOP) before and after the treatment were investigated.
RESULTS: 48 eyes in 48 patients satisfied the enrolment criteria (25 eyes in the latanoprost group, 23 eyes in the unoprostone group). At the end of the follow up period, iridial pigmentation was present in 15 patients (60.0%) in the latanoprost group and seven patients (30.4%) in the unoprostone group. The correlation between development of iridial pigmentation and age, sex, concurrent use of other ophthalmic solutions, and IOP reduction was not significant.
CONCLUSIONS: The incidence of iridial pigmentation induced by latanoprost or unoprostone is high in the case of long term treatment. Iridial pigmentation did not affect PG related ophthalmic solution induced IOP reduction.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12881333      PMCID: PMC1771820          DOI: 10.1136/bjo.87.8.956

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  [Increased iris pigmentation after use of latanoprost in Japanese brown eyes].

Authors:  T Hara
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2001-05

2.  Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.

Authors:  T Chiba; K Kashiwagi; S Kogure; K Abe; T Shibuya; M Furuichi; H Iijima; S Tsukahara
Journal:  J Glaucoma       Date:  2001-10       Impact factor: 2.503

3.  [The fine structure of melanocytes in the human iris].

Authors:  C E Dieterich
Journal:  Albrecht Von Graefes Arch Klin Exp Ophthalmol       Date:  1972

4.  Metabolites of isopropyl unoprostone as potential ophthalmic solutions to reduce intraocular pressure in pigmented rabbits.

Authors:  K Kashiwagi; Y Iizuka; S Tsukahara
Journal:  Jpn J Pharmacol       Date:  1999-09

5.  Prostaglandin-induced iridial pigmentation in primates.

Authors:  G Selén; J Stjernschantz; B Resul
Journal:  Surv Ophthalmol       Date:  1997-02       Impact factor: 6.048

6.  The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color.

Authors:  P J Wistrand; J Stjernschantz; K Olsson
Journal:  Surv Ophthalmol       Date:  1997-02       Impact factor: 6.048

7.  Iris-color change developed after topical isopropyl unoprostone treatment.

Authors:  T Yamamoto; Y Kitazawa
Journal:  J Glaucoma       Date:  1997-12       Impact factor: 2.503

8.  alpha-Methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro.

Authors:  F Drago; A Marino; C La Manna
Journal:  Exp Eye Res       Date:  1999-01       Impact factor: 3.467

Review 9.  Mechanism and clinical significance of prostaglandin-induced iris pigmentation.

Authors:  Johan W Stjernschantz; Daniel M Albert; Dan-Ning Hu; Filippo Drago; Per J Wistrand
Journal:  Surv Ophthalmol       Date:  2002-08       Impact factor: 6.048

10.  Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension.

Authors:  I Azuma; K Masuda; Y Kitazawa; M Takase; H Yamamura
Journal:  Jpn J Ophthalmol       Date:  1993       Impact factor: 2.447

View more
  5 in total

1.  Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma.

Authors:  Yoko Ikeda; Kazuhiko Mori; Kaori Tada; Morio Ueno; Shigeru Kinoshita; Chie Sotozono
Journal:  Clin Ophthalmol       Date:  2016-08-24

2.  The management of glaucoma and intraocular hypertension: current approaches and recent advances.

Authors:  Robert J Noecker
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

Review 3.  An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy.

Authors:  Derrick S Fung; Jess T Whitson
Journal:  Clin Ophthalmol       Date:  2014-03-10

4.  Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.

Authors:  Kazuhide Kawase; Jason L Vittitow; Robert N Weinreb; Makoto Araie
Journal:  Adv Ther       Date:  2016-07-25       Impact factor: 3.845

5.  Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice.

Authors:  Laura M Dutca; Danielle Rudd; Victor Robles; Anat Galor; Mona K Garvin; Michael G Anderson
Journal:  Sci Rep       Date:  2018-08-30       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.